Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-054822

Chief Executive Officer sold 7,500 shares at $14.89 ($111,683)

  • Chief Executive Officer acquired 7,500 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kauffman Michael · Chief Executive Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2020-10-12 Exercise or conversion : show line 1 in the form +1,424 $0.03 $47 757,913 I
2020-10-12 Exercise or conversion : show line 2 in the form +6,076 $0.03 $201 763,989 I
2020-10-12 Sale : show line 3 in the form −7,500 $14.89 $111,683 756,489 I
Open-market sales · 7,500 sh · avg $14.89 · $111,683

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2020-10-12 Exercise or conversion : show line 4 in the form Stock Option (right to buy) −1,424 $0.03 2020-10-31 1,424 0 I
2020-10-12 Exercise or conversion : show line 5 in the form Stock Option (right to buy) −6,076 $0.03 2020-10-31 6,076 0 I
Loading xslF345X03/doc4.xml…